LB Pharmaceuticals Inc (LBRX): Total Liabilities
$11.62M
As of 2025-12-31
$29.34M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.62M | -15.9% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $13.83M | n/a | 2026-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $11.62M | -15.9% |
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $39.78M | +54.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $19.12M | +0.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Liquidia Corp (LQDA) | 2025-12-31 | $283.19M | +87.6% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $422.65M | -4.3% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $53.23M | -17.4% |
Compare LBRX, AVIR, ADCT, SION side by side · Screen every company in Pharmaceutical Preparations ↗